Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication
HepACAGA proved to be effective and safe for treating patients with HCC and CRLM across a broad range of tumor sizes. These findings suggest that intermediate-sized tumors (3-5 cm) could be eligible for thermal ablation without compromising post-ablation recurrence.
Authors
- Rutger C. G. Bruijnen (ORCID: https://orcid.org/0000-0002-5167-4027)
- Martijn Intven (ORCID: https://orcid.org/0000-0002-5068-5517)
- Niek Wijnen (ORCID: https://orcid.org/0009-0001-1700-6930)
- Maarten L. J. Smits (ORCID: https://orcid.org/0000-0003-4735-655X)
- Joep de Bruijne
- Guus Martinus Bol (ORCID: https://orcid.org/0000-0002-4021-3823)
- Jeroen Hagendoorn (ORCID: https://orcid.org/0000-0001-8737-3923)
- Emma Ruijs
Institutions
- University of California, San Francisco (US)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- CardioVascular and Interventional Radiology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1007/s00270-025-04167-8
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29